Matches in Ubergraph for { <http://purl.obolibrary.org/obo/NCIT_C39015> ?p ?o ?g. }
Showing items 1 to 19 of
19
with 100 items per page.
- NCIT_C39015 NCIT_NHC0 "C39015" @default.
- NCIT_C39015 NCIT_P106 "Functional Concept" @default.
- NCIT_C39015 NCIT_P108 "Anandamide Metabolism Pathway" @default.
- NCIT_C39015 NCIT_P207 "C1515961" @default.
- NCIT_C39015 NCIT_P216 "h_cb1rPathway" @default.
- NCIT_C39015 NCIT_P325 "The lipid anandamide derived from arachidonic acid binds to the cannabinoid G-protein coupled receptors CB-1 and CB-2 to exert its biological effects. The CB-1 receptor is also the site of action of the psychoactive components of marijuana, including tetrahydrocannabinol (THC), and responsible for the effects of cannabinoids to repress learning, memory, and anxiety, relieve pain and nausea, and to stimulate appetite. The CB-2 receptor is expressed mainly in cells of the immune system and appears to modulate immune functions, but not to be involved in the effects of cannabinoids in the central nervous system. In addition to the illicit use of cannabinoids as drugs of abuse, the pharmaceutical use of natural and synthetic cannabinoids is being intensely studied, including a possible role in neurodegenerative diseases. Another therapeutic approach is the pharmacological modulation of levels of the endogenous cannabinoid anandamide. Although the subject of some controversy, the most likely route for the biosynthesis of anandamide starts with the formation of phosphatidylethanolamine from arachidonic acid and ethanolamine. Phosphatidylethanolamine is converted by N-acyltransferase to the phospholipid N-arachidonoyl-phosphatidylethanolamine (NAPE) and hydrolysis by phospholipase D releases phosphatidic acid and anandamide, which binds to the cannabinoid receptors. The signal it induces is terminated in part by degradation of anandamide by anandamide hydrolase (FAAH). 2-arachidonoyl-glycerol (2-AG) and 2-arachidonoyl glyceryl ether have also been shown to bind the cannabinoid receptors, and has been suggested to be important endocannabinoids. Also complicating cannabinoid pharmacology is the suggestion that some effects of cannabinoids might be moderated by additional receptor subtypes that have not yet been identified or by the vanilloid receptors. (This definition may be outdated - see the DesignNote.)" @default.
- NCIT_C39015 NCIT_P366 "Anandamide_Metabolism_Pathway" @default.
- NCIT_C39015 NCIT_P98 "The BIOCARTA Definition (ALT_DEFINITION) for this pathway concept was provided by BioCarta. This property was not created by, nor is it maintained by the NCI Thesaurus staff. Additionally, BioCarta is no longer updating its pathway data; thus, the BIOCARTA Definition might be outdated or inaccurate. Please see the Terms and Conditions for Use at http://www.biocarta.com/." @default.
- NCIT_C39015 normalizedInformationContent "100" @default.
- NCIT_C39015 referenceCount "1" @default.
- NCIT_C39015 hasExactSynonym "Anandamide Metabolism Pathway" @default.
- NCIT_C39015 hasExactSynonym "Metabolism of Anandamide, an Endogenous Cannabinoid" @default.
- NCIT_C39015 type Class @default.
- NCIT_C39015 isDefinedBy ncit.owl @default.
- NCIT_C39015 label "Anandamide Metabolism Pathway" @default.
- NCIT_C39015 subClassOf NCIT_C18611 @default.
- NCIT_C39015 subClassOf NCIT_C20633 @default.
- NCIT_C39015 subClassOf NCIT_C39015 @default.
- NCIT_C39015 subClassOf NCIT_C39728 @default.